Abstract
Cancer is a disease caused by the alteration of proto-oncogenes and tumor suppressor genes, has a high prevalence in the population, and is one of the main causes of death worldwide. For its treatment, there are different therapy options; however, these are not always effective for all existing types of cancer, which gives rise to the search for new compounds. The objective of this work is to determine the degree of cytotoxic activity of naphthoxyacetamide using dose–response curves in a cell viability assay. For this, the cytotoxic effects of N-(2-morpholinoethyl)-2-(naphthalen-2-yloxy) were identified in cancer cells (HeLa) based on the metabolic reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenylretrazol (MTT) bromide. The cell cultures were seeded at a density of 5000 cells/well in 96-well plates and treated by hexapplication with various concentrations of the compounds to be tested (0.31–3.16 µM/mL) for 24 h. Microplates were read in an ELISA reader at 575 nm. The dose–response curve of N-(2-morpholinoethyl)-2-(naphthalen-2-yloxy)acetamide (3.16, 1.77, 1, 0.31 µM/mL) showed that at a concentration of 3.16 µM/mL, it presents cytotoxic effects similar to those shown by the drug reference (cisplatin 3.32 µM/mL). In conclusion, N-(2-morpholinoethyl)-2-(naphthalen-2-yloxy)acetamide showed cytotoxic effects similar to cisplatin.
Supplementary Materials
The following are available online at https://www.mdpi.com/article/10.3390/ECMC2022-13304/s1.
Author Contributions
Conceptualization, C.P.-G. and M.Á.Z.-S.; methodology, C.M.-N.; software, C.A.M.-C.; validation, C.A.M.-C., C.P.-G. and M.Á.Z.-S.; formal analysis, C.M.-N., C.A.M.-C., C.P.-G. and M.Á.Z.-S.; investigation, C.M.-N. All authors have read and agreed to the published version of the manuscript.
Funding
Cristina Martínez-Nava was supported by grants for doctoral studies from CONACyT Scholarship 858818.
Institutional Review Board Statement
Not applicable.
Informed Consent Statement
Not applicable.
Conflicts of Interest
The authors declare no conflict of interest.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).